Filana Therapeutics (FLNA) Stock Overview
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FLNA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Filana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.73 |
| 52 Week High | US$4.98 |
| 52 Week Low | US$1.15 |
| Beta | -0.68 |
| 1 Month Change | -21.72% |
| 3 Month Change | -17.22% |
| 1 Year Change | 33.08% |
| 3 Year Change | -92.78% |
| 5 Year Change | -95.84% |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
Mar 04Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Nov 07Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Shareholder Returns
| FLNA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.6% | 2.7% | 1.9% |
| 1Y | 33.1% | 29.6% | 23.7% |
Return vs Industry: FLNA exceeded the US Pharmaceuticals industry which returned 29.6% over the past year.
Return vs Market: FLNA exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| FLNA volatility | |
|---|---|
| FLNA Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: FLNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FLNA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 19 | Rick Barry | www.filanatx.com |
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026.
Filana Therapeutics, Inc. Fundamentals Summary
| FLNA fundamental statistics | |
|---|---|
| Market cap | US$83.57m |
| Earnings (TTM) | -US$90.97m |
| Revenue (TTM) | n/a |
Is FLNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLNA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$26.59m |
| Gross Profit | -US$26.59m |
| Other Expenses | US$64.38m |
| Earnings | -US$90.97m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FLNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/03 14:24 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Filana Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Fraser | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Elemer Piros | Lucid Capital Markets |